Oromucosal solutions of zolpidem or pharmaceutically acceptable salts thereof
US12133845B2 · kind B2 · utility
0Cited by
0References
13Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 4, 2019 |
| Grant date | Nov 5, 2024 |
| Priority date | — |
| Expiry date | May 23, 2041 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P25/20
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to buccal or sublingual formulations of Zolpidem or pharmaceutically acceptable salt thereof. The formulations minimize the amount of penetration enhancers and yet provide rapid transmucosal penetration of the drug. These formulations not only provide desired a concentration (0.5% to 10% w/v) of the drug in the form of clear solution, but also achieve stable formulations throughout the shelf-life of at least about 2 years. The pH of the stable non-aqueous solutions of the present invention is in the range of range of 5 to 9, preferably 6 to 9 more preferably 7 to 9.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.